Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection

Helicobacter

Volumn 12, Issue 6, 2007, Pages 633-637

  Wu, I Chen ^a,b   Wu, Deng Chyang ^a,b   Hsu, Ping I ^c   Lu, Chien Yu ^a   Yu, Fang Jung ^a   Wang, Tsang En ^d   Chang, Wen Hsiung ^d   Chen, Jyh Jon ^e   Kuo, Fu Chen ^f   Wu, Jeng Yih ^a   Wang, Wen Ming ^a,b   Bair, Ming Jong ^d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d MACKAY MEMORIAL HOSPITAL   (Taiwan)

^e CHI MEI MEDICAL CENTER   (Taiwan)

^f I SHOU UNIVERSITY   (Taiwan)

Author keywords

Esomeprazole; Helicobacter pylori; Proton pump inhibitor; Rabeprazole; Triple therapy

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; ESOMEPRAZOLE; RABEPRAZOLE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ARTICLE; BIOPSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; ENDOSCOPY; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TAIWAN; TASTE DISORDER; TREATMENT RESPONSE; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PATIENT COMPLIANCE; PROTON PUMP INHIBITORS;

HELICOBACTER PYLORI;

EID: 36248964131     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00553.x     Document Type: Article

References (23)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 1994 272 : 65 9.
2. Teh BH, Lin JT, Pan WH, Lin SH, Wang LY, Lee TK, Chen CJ. Seroprevalence and associated risk factors of Helicobacter pylori infection in Taiwan. Anticancer Res 1994 14 : 1389 92.
3. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007 Jun 56 (6 772 81.
4. Bytzer P, O'Morain C. Treatment of Helicobacter pylori. Helicobacter 2005 10 : 40 6.
5. Kim JG. Treatment of Helicobacter pylori infection. Korean J Gastroenterol 2005 46 : 172 80.
6. Dupas JL. First line therapy for Helicobacter pylori eradication in France. Gastroenterol Clin Biol 2003 27 : 467 72.
7. Spengler G, Molnar A, Klausz G, Mandi Y, Kawase M, Motohashi N, Molnar J. Inhibitory action of a new proton pump inhibitor, trifluoromethyl ketone derivative, against the motility of clarithromycin-susceptible and-resistant Helicobacter pylori. Int J Antimicrob Agents 2004 23 : 631 3.
8. Figura N, Crabtree JE, Dattilo M. In-vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother 1997 39 : 585 90.
9. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005 20 : 153 67.
10. Sharara AI. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication. Expert Rev Anti Infect Ther 2005 3 : 863 70.
11. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006 101 : 1467 75.
12. Hsu PI, Lai KH, Lin CK, et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol 2005 100 : 2387 92.
13. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998 12 : 1079 89.
14. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999 13 : 3 10.
15. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review: rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003 17 : 751 64.
16. Wu IC, Ke HL, Lo YC, Yang YC, Chuang CH, Yu FJ, Lee YC, Jan CM, Wang WM, Wu DC. Evaluation of a newly developed office-based stool test for detecting Helicobacter pylori: an extensive pilot study. Hepatogastroenterology 2003 50 : 1761 5.
17. Machin D, Campbell M, Fayers P, Pinol A. Sample Size Tables for Clinical Studies, 2nd edn. Oxford, UK: Blackwell Science, London, England, 1997.
18. Miwa H, Yamada T, Sato K, Ohta K, Ohkura R, Murai T, Nagahara A, Takei Y, Ogihara T, Sato N. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole. Dig Dis Sci 2000 45 : 77 82.
19. Tan HJ, Rizal AM, Rosmadi MY, Goh KL. Distribution of Helicobacter pylori cagA, cagE and vacA in different ethnic groups in Kuala Lumpur, Malaysia. J Gastroenterol Hepatol 2005 20 : 589 94.
20. Cho I, Blaser MJ, Francois F, Mathew JP, Ye XY, Goldberg JD, Bini EJ. Helicobacter pylori and overweight status in the United States: data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2005 162 : 579 84.
21. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyren O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004 96 : 388 96.
22. Hassan-Alin M, Andersson T, Bredberg E, Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000 56 : 665 70.
23. Dent J. Review article: pharmacology of esomeprazole and comparisons with omeprazole. Aliment Pharmacol Ther 2003 17 : 5 9